Prognostic Factors Of Erdheim–Chester Disease: A Nationwide Survey In Japan
EHA Learning Center. Toya T. Nov 1, 2018; 234398
Topic: 5E Genetics and molecular biology
Takashi Toya
Takashi Toya
Login now to access Regular content available to all registered users.

Access to EHA Members only content is an EHA membership benefit.
Click here to join EHA or renew your membership here.


Journal Abstract
Discussion Forum (0)
Rate & Comment (0)

Co-Authors: Mizuki Ogura, Kazuhiro Toyama, Akihide Yoshimi, Aya Shinozaki-Ushiku, Akira Honda, Kenjiro Honda, Noriko Hosoya, Yukako Murakami, Hiroyuki Kawashima, Yasuhito Nannya, Shunya Arai, Fumihiko Nakamura, Yusuke Shinoda, Masaomi Nangaku, Kiyoshi Miyagawa, Masashi Fukayama, Akiko Moriya-Saito, Ichiro Katayama, Takashi Ogura, Mineo Kurokawa

Abstract: Erdheim–Chester disease is a rare histiocytosis with insufficient clinical data. To clarify the clinical features and prognostic factors of Erdheim–Chester disease, we conducted a nationwide survey to collect the detailed data of 44 patients with Erdheim–Chester disease in Japan. The median age of onset of the participants was 51 (range: 23–76) years, and the median number of involved organs per patient was 4 (range: 1–11). The existence of central nervous system disease was correlated with older age (P=0.033), the presence of cardiovascular lesions (P=0.015), and an increased number of involved organs (P=0.0042). The median survival from the onset was 10.4 years, and >3.0 mg/dL C-reactive protein level at onset was associated with worse outcome (median survival, 14.6 vs. 7.4 years; P=0.0016). In a multivariate analysis, age >60 years (hazard ratio, 25.9; 95% confidence interval, 2.82–237; P=0.0040) and the presence of digestive organ involvement (hazard ratio, 4.74; 95% confidence interval, 1.05–21.4; P=0.043) were correlated with worse survival. Fourteen patients had available histological samples of Erdheim– Chester disease lesions. BRAFV600E mutation was detected in 11 patients (78%) by Sanger sequencing. A correlation between BRAF mutation status and clinical factors was not observed. Our study revealed that age and digestive organ involvement influence the outcome of Erdheim–Chester disease patients, and an inflammatory marker, such as C-reactive protein, might reflect the activity of this inflammatory myeloid neoplasm.

Article Number: 1815

Doi: 10.3324/haematol.2018.190728

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings